The phase I/II IDeate-Pantumor01 trial (NCT04145622) evaluated ifinatamab deruxtecan (I-DXd), a novel B7-H3-directed ADC, in heavily pretreated patients with CRPC, esophageal squamous cell carcinoma (ESCC), sqNSCLC, and SCLC, showing encouraging antitumor activity irrespective of histology [117]. The gene discussed is CD276; the disease is esophageal squamous cell carcinoma.